読み込み中
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
前日終値
$0.638
−$0.0121 · -1.86%
日中の時刻はETです。市場データは遅延する場合があります。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日中レンジ
現在 $0.638
52週レンジ
現在 $0.638
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
32
割高
センチメント
67
強気
リスク
63
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日中レンジ
現在 $0.638
52週レンジ
現在 $0.638
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 470.6万 USD | 434.6万 USD | 242.8万 USD | 37.7万 USD | 50万 USD |
| 売上原価 | 754.2万 USD | 826.6万 USD | 847.8万 USD | 361.4万 USD | 58.5万 USD |
| 粗利益 | −283.6万 USD | −392万 USD | −605万 USD | −323.7万 USD | −8.5万 USD |
| 研究開発 | 56.78億 USD | 599.2万 USD | 725.2万 USD | 1146.6万 USD | 929.6万 USD |
| 販売・一般管理 | 415.77億 USD | 366.19億 USD | 3565.8万 USD | 3981.9万 USD | 1803.8万 USD |
| 営業費用 | 4680.4万 USD | 4213.2万 USD | 4243.2万 USD | 5293.4万 USD | 2733.4万 USD |
| 受取利息 | 38.6万 USD | 32.2万 USD | 42.4万 USD | 8.8万 USD | — |
| 支払利息 | 2.2万 USD | 2.6万 USD | 41.6万 USD | 8000 USD | 65.9万 USD |
| 減価償却費と償却費 | 87.2万 USD | 116.7万 USD | 249.9万 USD | 193.6万 USD | 4000 USD |
| 営業利益 | −4964万 USD | −4605.2万 USD | −4848.2万 USD | −5617.1万 USD | −2741.9万 USD |
| 純利益 | −5801万 USD | −4552.9万 USD | −5266.6万 USD | −5617.1万 USD | −2807.8万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.00
上昇余地（213.48%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI444.97万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM237.01万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF182.16万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO90.44万0.01%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO83.37万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC31.58万0.02%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG15.84万0.01%17億 USD0.06%$260.49+0.91%
iShares Russell 2500 ETFSMMD4.98万0.00%40.62億 USD0.23%$86.29+0.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
